![]() Immuno-Therapy Targeting Multiple Cancers with High Unmet Need Ampligen is also being used to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center. Received Orphan Drug Designation for Ampligen ® (rintatolimod) for the treatment of Ebola Virus Disease.Īnnounced FDA clearance of IND application to evaluate Ampligen in Phase 2 clinical study for the treatment of post-COVID conditions.Ĭommenced enrollment with study collaborator, Roswell Park, in an NCI-funded Phase 2 clinical trial evaluating Ampligen in primary PD-1/PD-L1 Resistant Melanoma.Īnnounced commencement of Phase 2 study of Ampligen for the treatment of Pancreatic Cancer.Īmpligen is being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the U.S. Presented positive data from research led by Roswell Park Comprehensive Cancer Center medical oncologist, Shipra Gandhi, MD, evaluating Ampligen ® (rintatolimod) as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer (TNBC) at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting. We have been, and will continue to be, committed to generating near- and long-term value for all stakeholders,” commented Thomas K. As we enter the final stretch for 2022, I believe we are well-positioned to reach the value-driving catalysts across our pipeline. Not only have we delivered on our commitments by initiating studies, but we have also commenced enrollment and are on track to reach targeted milestones that lay on the horizon. I am incredibly pleased with the progress we’ve made and am excited for what remains ahead of us. “Over the course of 2022 and throughout this past quarter, we have remained focused on successfully executing on our clinical development programs. (NYSE American: AIM) (“AIM” or the “Company”), an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported its financial results for the third quarter 2022 and provided a business update. 15, 2022 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. – Cash position expected to fund operations through end of 2023 Additionally, Ampligen is approved in Argentina for the treatment of severe chronic fatigue syndrome (CFS) and is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions.įor more information, please visit and connect with the Company on Twitter, LinkedIn, and Facebook.– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones The Company also has multiple ongoing clinical trials to evaluate Ampligen as a combinational therapy for the treatment of a variety of solid tumor types both underway and planned at major cancer research centers. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.Īmpligen is currently being used to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM has commenced a Phase 2 clinical study in locally advanced pancreatic cancer. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.ĪIM ImmunoTech Inc. Equels will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023, at 11:00 AM ET.Ī live video webcast of the presentation will be available on the Events & Presentations page of the Company’s website ( ). ![]() (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases - including COVID-19, the disease caused by the SARS-CoV-2 virus - today announced that AIM Chief Executive Officer Thomas K. 05, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. Live video webcast on Wednesday, January 18th at 11:00 AM ET
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |